Activation of the NF‐κB pathway stimulates a proinflammatory response and promotes renal fibrosis, and treatment with an NF-κB inhibitor attenuates renal injury and inflammation in CKD tissues (30–32). This evidence concerns the gene NFKB1 and chronic kidney disease.